<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Visser, P.</title>
    <link>http://repub.eur.nl/res/aut/432/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Cell autonomy of the mouse claw paw mutation. (Article)</title>
      <link>http://repub.eur.nl/res/pub/2659/</link>
      <pubDate>2004-08-15T00:00:00Z</pubDate>
      <description>Mice homozygous for the autosomal recessive mutation claw paw (clp) are characterized by limb posture abnormalities and congenital hypomyelination, with delayed onset of myelination of the peripheral nervous system but not the central nervous system. Although this combination of limb and peripheral nerve abnormalities in clp/clp mice might suggest a common neurogenic origin of the syndrome, it is not clear whether the clp gene acts primarily in the neurone, the Schwann cell or both. In the work described here, we address this question of cell autonomy of the clp mutation through reciprocal nerve grafting experiments between wild-type and clp/clp animals. Our results demonstrate that the clp mutation affects the Schwann cell compartment and possibly also the neuronal compartment. These data suggest that the clp gene product is expressed in Schwann cells as well as neurones and is likely to be involved in direct axon--Schwann cell interactions. Within the Schwann cell, clp affects a myelin-related signaling pathway that regulates periaxin and Krox-20 expression, but not Oct-6.</description>
    </item> <item>
      <title>Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses (Article)</title>
      <link>http://repub.eur.nl/res/pub/10237/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>The presence of porcine endogenous retroviruses presents a potential risk
      of transmission of infectious diseases (xenozoonosis) if tissues and
      organs from genetically modified pigs are to be used in
      xenotransplantation. Here, we report that intracellular expression of a
      llama single-domain antibody against p15, the matrix domain protein of the
      porcine endogenous retrovirus Gag polyprotein, blocks retrovirus
      production, providing the possibility of eliminating the risk of infection
      in xenotransplantation.</description>
    </item> <item>
      <title>Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13113/</link>
      <pubDate>2002-12-13T00:00:00Z</pubDate>
      <description>Plasma phospholipid transfer protein (PLTP) is thought to be involved in
      the remodeling of high density lipoproteins (HDL), which are
      atheroprotective. It is also involved in the metabolism of very low
      density lipoproteins (VLDL). Hence, PLTP is thought to be an important
      factor in lipoprotein metabolism and the development of atherosclerosis.
      We have overexpressed PLTP in mice heterozygous for the low density
      lipoprotein (LDL) receptor, a model for atherosclerosis. We show that
      increased PLTP activity results in a dose-dependent decrease in HDL, and a
      moderate stimulation of VLDL secretion (&lt;/=1.5-fold). The mice were given
      a high fat, high cholesterol diet, which resulted in hypercholesterolemia
      in all animals. HDL concentrations were dramatically reduced in
      PLTP-overexpressing animals when compared with LDL receptor controls,
      whereas VLDL + LDL cholesterol levels were identical. Susceptibility to
      atherosclerosis was increased in a PLTP dose-responsive manner. We
      conclude that PLTP increases susceptibility to atherosclerosis by lowering
      HDL concentrations, and therefore we suggest that an increase in PLTP is a
      novel, long term risk factor for atherosclerosis in humans.</description>
    </item> <item>
      <title>Developmental defects and male sterility in mice lacking the ubiquitin-like DNA repair gene mHR23B (Article)</title>
      <link>http://repub.eur.nl/res/pub/31840/</link>
      <pubDate>2002-02-05T00:00:00Z</pubDate>
      <description>mHR23B encodes one of the two mammalian homologs of Saccharomyces cerevisiae RAD23, a ubiquitin-like fusion protein involved in nucleotide excision repair (NER). Part of mHR23B is complexed with the XPC protein, and this heterodimer functions as the main damage detector and initiator of global genome NER. While XPC defects exist in humans and mice, mutations for mHR23A and mHR23B are not known. Here, we present a mouse model for mHR23B. Unlike XPC-deficient cells, mHR23B-/-mouse embryonic fibroblasts are not UV sensitive and retain the repair characteristics of wild-type cells. In agreement with the results of in vitro repair studies, this indicates that mHR23A can functionally replace mHR23B in NER. Unexpectedly, mHR23B-/-mice show impaired embryonic development and a high rate (90%) of intrauterine or neonatal death. Surviving animals display a variety of abnormalities, including retarded growth, facial dysmorphology, and male sterility. Such abnormalities are not observed in XPC and other NER-deficient mouse mutants and point to a separate function of mHR23B in development. This function may involve regulation of protein stability via the ubiquitin/proteasome pathway and is not or only in part compensated for by mHR23A.</description>
    </item> <item>
      <title>Developmental defects and male sterility in mice lacking the ubiquitin-like DNA repair gene mHR23B. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3193/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>mHR23B encodes one of the two mammalian homologs of Saccharomyces cerevisiae RAD23, a ubiquitin-like fusion protein involved in nucleotide excision repair (NER). Part of mHR23B is complexed with the XPC protein, and this heterodimer functions as the main damage detector and initiator of global genome NER. While XPC defects exist in humans and mice, mutations for mHR23A and mHR23B are not known. Here, we present a mouse model for mHR23B. Unlike XPC-deficient cells, mHR23B(-/-) mouse embryonic fibroblasts are not UV sensitive and retain the repair characteristics of wild-type cells. In agreement with the results of in vitro repair studies, this indicates that mHR23A can functionally replace mHR23B in NER. Unexpectedly, mHR23B(-/-) mice show impaired embryonic development and a high rate (90%) of intrauterine or neonatal death. Surviving animals display a variety of abnormalities, including retarded growth, facial dysmorphology, and male sterility. Such abnormalities are not observed in XPC and other NER-deficient mouse mutants and point to a separate function of mHR23B in development. This function may involve regulation of protein stability via the ubiquitin/proteasome pathway and is not or only in part compensated for by mHR23A.</description>
    </item> <item>
      <title>Mammalian Golgi-associated Bicaudal-D2 functions in the dynein-dynactin pathway by interacting with these complexes. (Article)</title>
      <link>http://repub.eur.nl/res/pub/12944/</link>
      <pubDate>2001-08-01T00:00:00Z</pubDate>
      <description>Genetic analysis in Drosophila suggests that Bicaudal-D functions in an
      essential microtubule-based transport pathway, together with cytoplasmic
      dynein and dynactin. However, the molecular mechanism underlying
      interactions of these proteins has remained elusive. We show here that a
      mammalian homologue of Bicaudal-D, BICD2, binds to the dynamitin subunit
      of dynactin. This interaction is confirmed by mass spectrometry,
      immunoprecipitation studies and in vitro binding assays. In interphase
      cells, BICD2 mainly localizes to the Golgi complex and has properties of a
      peripheral coat protein, yet it also co-localizes with dynactin at
      microtubule plus ends. Overexpression studies using green fluorescent
      protein-tagged forms of BICD2 verify its intracellular distribution and
      co-localization with dynactin, and indicate that the C-terminus of BICD2
      is responsible for Golgi targeting. Overexpression of the N-terminal
      domain of BICD2 disrupts minus-end-directed organelle distribution and
      this portion of BICD2 co-precipitates with cytoplasmic dynein. Nocodazole
      treatment of cells results in an extensive BICD2-dynactin-dynein
      co-localization. Taken together, these data suggest that mammalian BICD2
      plays a role in the dynein- dynactin interaction on the surface of
      membranous organelles, by associating with these complexes.</description>
    </item> <item>
      <title>Branching and differentiation defects in pulmonary epithelium with elevated GATA6 expression. (Article)</title>
      <link>http://repub.eur.nl/res/pub/2607/</link>
      <pubDate>2001-07-09T00:00:00Z</pubDate>
      <description>The transcription factor GATA6 is expressed in the fetal pulmonary epithelium of the developing mouse lung and loss of function studies strongly suggested that it is required for proper branching morphogenesis and epithelial differentiation. We have further investigated the role of GATA6 in this process by utilizing a pulmonary epithelium specific promoter to maintain high levels of GATA6 protein during fetal lung development. Transgenic mice expressing Gata6 cDNA under the control of the human Surfactant Protein-C (SP-C) promoter were generated and their lungs were analyzed during fetal stages. Transgenic lungs exhibit branching defects as early as embryonic day (E) 14.5 and molecular analysis just before birth (E18.5) shows a lack of distal epithelium differentiation whereas proximal epithelium is unaffected. Electron microscopic analysis and glycogen staining confirm the lack of differentiation to mature Type II cells. Thus, elevated levels of GATA6 protein affect early lung development and in analogy to other GATA factors in other tissues, GATA6 also plays a crucial role in the terminal differentiation in this case of the distal pulmonary epithelium.</description>
    </item> <item>
      <title>A distal Schwann cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral nerve development and regeneration. (Article)</title>
      <link>http://repub.eur.nl/res/pub/12878/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>The POU domain transcription factor Oct-6 is a major regulator of Schwann
          cell differentiation and myelination. During nerve development and
          regeneration, expression of Oct-6 is under the control of axonal signals.
          Identification of the cis-acting elements necessary for Oct-6 gene
          regulation is an important step in deciphering the complex signalling
          between Schwann cells and axons governing myelination. Here we show that a
          fragment distal to the Oct-6 gene, containing two DNase I-hypersensitive
          sites, acts as the Oct-6 Schwann cell-specific enhancer (SCE). The SCE is
          sufficient to drive spatially and temporally correct expression, during
          both normal peripheral nerve development and regeneration. We further
          demonstrate that a tagged version of Oct-6, driven by the SCE, rescues the
          peripheral nerve phenotype of Oct-6-deficient mice. Thus, our isolation
          and characterization of the Oct-6 SCE provides the first description of a
          cis-acting genetic element that responds to converging signalling pathways
          to drive myelination in the peripheral nervous system.</description>
    </item> <item>
      <title>CFU-S(11) activity does not localize solely with the aorta in the aorta-gonad-mesonephros region (Article)</title>
      <link>http://repub.eur.nl/res/pub/9482/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>The aorta-gonad-mesonephros (AGM) region is a potent hematopoietic site in
          the midgestation mouse conceptus and first contains colony-forming
          units-spleen day 11 (CFU-S(11)) at embryonic day 10 (E10). Because
          CFU-S(11) activity is present in the AGM region before the onset of
          hematopoietic stem cell (HSC) activity, CFU-S(11) activity in the complex
          developing vascular and urogenital regions of the AGM was localized. From
          E10 onward, CFU-S(11) activity is associated with the aortic vasculature,
          and is found also in the urogenital ridges (UGRs). Together with data
          obtained from organ explant cultures, in which up to a 16-fold increase in
          CFU-S(11) activity was observed, it was determined that CFU-S(11) can be
          increased autonomously both in vascular sites and in UGRs. Furthermore,
          CFU-S(11) activity is present in vitelline and umbilical vessels. This,
          together with the presence of CFU-S(11) in the UGRs 2 days before HSC
          activity, suggests both temporally and spatially distinct emergent sources
          of CFU-S(11). (Blood. 2000;96:2902-2904)</description>
    </item> <item>
      <title>New rat model that phenotypically resembles autosomal recessive polycystic kidney disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/9545/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Numerous murine models of polycystic kidney disease (PKD) have been
          described. While mouse models are particularly well suited for
          investigating the molecular pathogenesis of PKD, rats are well established
          as an experimental model of renal physiologic processes. Han:SPRD-CY: rats
          have been proposed as a model for human autosomal dominant PKD. A new
          spontaneous rat mutation, designated wpk, has now been identified. In the
          mutants, the renal cystic phenotype resembles human autosomal recessive
          PKD (ARPKD). This study was designed to characterize the clinical and
          histopathologic features of wpk/wpk mutants and to map the wpk locus.
          Homozygous mutants developed nephromegaly, hypertension, proteinuria,
          impaired urine-concentrating capacity, and uremia, resulting in death at 4
          wk of age. Early cysts were present in the nephrogenic zone at embryonic
          day 19. These were localized, by specific staining and electron
          microscopy, to differentiated proximal tubules, thick limbs, distal
          tubules, and collecting ducts. In later stages, the cysts were largely
          confined to collecting ducts. Although the renal histopathologic features
          are strikingly similar to those of human ARPKD, wpk/wpk mutants exhibited
          no evidence of biliary tract abnormalities. The wpk locus maps just
          proximal to the CY: locus on rat chromosome 5, and complementation studies
          demonstrated that these loci are not allelic. It is concluded that the
          clinical and renal histopathologic features of this new rat model strongly
          resemble those of human ARPKD. Although homology mapping indicates that
          rat wpk and human ARPKD involve distinct genes, this new rat mutation
          provides an excellent experimental model to study the molecular
          pathogenesis and renal pathophysiologic features of recessive PKD.</description>
    </item> <item>
      <title>A Gp96/GRP94 is a putative high density lipoprotein-binding protein in liver. (Article)</title>
      <link>http://repub.eur.nl/res/pub/2588/</link>
      <pubDate>1999-03-25T00:00:00Z</pubDate>
      <description>We have previously shown that three high density lipoproteins (HDL)-binding proteins in liver, of 90, 110 and 180 kDa, are structurally related. In this study, these proteins are identified as gp96/GRP94. This protein is known to occur as a homodimer and has a dual subcellular localization: it is both an endoplasmic reticulum resident protein, where it is supposed to act as a chaperonin, and a plasma membrane protein, whose significance is unknown. In ultrastructural studies the plasma membrane localization of the homodimeric form was verified. The 90-kDa protein was abundantly present at the membranes of the endosomal/lysosomal vesicles as well as at the apical hepatocyte membranes, comprising the bile canaliculi. The monomeric protein is scarcely present at the basolateral membrane of the hepatocytes, but could be demonstrated in coated pits, suggesting involvement in receptor-mediated endocytosis. Labeling of the endoplasmic reticulum was virtually absent. Gp96/GRP94 was transiently expressed in COS-1 cells. However, the expressed protein was exclusively localized in the endoplasmic reticulum. Transfection with constructs in which the C-terminal KDEL sequence had been deleted, resulted in plasma membrane localized expression of protein, but only in an extremely low percentage of cells. In order to evaluate the HDL-binding capacities of this protein, stably transfected cells were generated, using several cell types. It appeared to be difficult to obtain a prolonged high level expression of gp96. In these cases, however, a marked increase of HDL-binding activity compared with the control cells could be observed.</description>
    </item> <item>
      <title>Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II (Article)</title>
      <link>http://repub.eur.nl/res/pub/9189/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Pompe's disease or glycogen storage disease type II (GSDII) belongs to the
          family of inherited lysosomal storage diseases. The underlying deficiency
          of acid alpha-glucosidase leads in different degrees of severity to
          glycogen storage in heart, skeletal and smooth muscle. There is currently
          no treatment for this fatal disease, but the applicability of enzyme
          replacement therapy is under investigation. For this purpose, recombinant
          human acid alpha-glucosidase has been produced on an industrial scale in
          the milk of transgenic rabbits. In this paper we demonstrate the
          therapeutic effect of this enzyme in our knockout mouse model of GSDII.
          Full correction of acid alpha-glucosidase deficiency was obtained in all
          tissues except brain after a single dose of i.v. enzyme administration.
          Weekly enzyme infusions over a period of 6 months resulted in degradation
          of lysosomal glycogen in heart, skeletal and smooth muscle. The tissue
          morphology improved substantially despite the advanced state of disease at
          the start of treatment. The results have led to the start of a Phase II
          clinical trial of enzyme replacement therapy in patients.</description>
    </item> <item>
      <title>Comparison of sequence and function of the Oct-6 genes in zebrafish, chicken and mouse. (Article)</title>
      <link>http://repub.eur.nl/res/pub/2562/</link>
      <pubDate>1998-06-01T00:00:00Z</pubDate>
      <description>To examine the role of the Oct-6 gene in Schwann cell differentiation we have cloned and characterized the chicken and zebrafish homologues of the mouse Oct-6 gene. While highly homologous in the Pit1-Oct1/2-Unc86 (POU) domain, sequence similarities are limited outside this domain. Both genes are intronless and both proteins lack the amino acid repeats that are a characteristic feature of the mammalian Oct-6 proteins. However as in mammals, the aminoterminal parts of the chicken and zebrafish Oct-6 proteins are essential for transactivation of octamer containing promoters. By immunohistochemistry we have found that the chicken Oct-6 protein is expressed in late embryonic ensheathing Schwann cells of the sciatic nerve and is rapidly downregulated when myelination proceeds. This expression profile in glial cells is identical to that in the mouse and rat. Furthermore the zebrafish Oct-6 homolog is expressed in the posterior lateral nerve at a time when it contains actively myelinating Schwann cells. Thus despite extensive primary sequence divergence among the vertebrate Oct-6 proteins, the expression of the chicken and zebrafish Oct-6 proteins is consistent with the notion that Oct-6 functions as a 'competence factor' in promyelin cells to execute the myelination program.</description>
    </item> <item>
      <title>A mouse model for the basal transcription/DNA repair disorder trichothiodystrophy. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3141/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>The sun-sensitive form of the severe neurodevelopmental, brittle hair disorder trichothiodystrophy (TTD) is caused by point mutations in the essential XPB and XPD helicase subunits of the dual functional DNA repair/basal transcription factor TFIIH. The phenotype is hypothesized to be in part derived from a nucleotide excision repair defect and in part from a subtle basal transcription deficiency accounting for the nonrepair TTD features. Using a novel gene-targeting strategy, we have mimicked the causative XPD point mutation of a TTD patient in the mouse. TTD mice reflect to a remarkable extent the human disorder, including brittle hair, developmental abnormalities, reduced life span, UV sensitivity, and skin abnormalities. The cutaneous symptoms are associated with reduced transcription of a skin-specific gene strongly supporting the concept of TTD as a human disease due to inborn defects in basal transcription and DNA repair.</description>
    </item> <item>
      <title>Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/8754/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>Glycogen storage disease type II (GSDII; Pompe disease), caused by
          inherited deficiency of acid alpha-glucosidase, is a lysosomal disorder
          affecting heart and skeletal muscles. A mouse model of this disease was
          obtained by targeted disruption of the murine acid alpha-glucosidase gene
          (Gaa) in embryonic stem cells. Homozygous knockout mice (Gaa -/-) lack Gaa
          mRNA and have a virtually complete acid alpha-glucosidase deficiency.
          Glycogen-containing lysosomes are detected soon after birth in liver,
          heart and skeletal muscle cells. By 13 weeks of age, large focal deposits
          of glycogen have formed. Vacuolar spaces stain positive for acid
          phosphatase as a sign of lysosomal pathology. Both male and female
          knockout mice are fertile and can be intercrossed to produce progeny. The
          first born knockout mice are at present 9 months old. Overt clinical
          symptoms are still absent, but the heart is typically enlarged and the
          electrocardiogram is abnormal. The mouse model will help greatly to
          understand the pathogenic mechanism of GSDII and is a valuable instrument
          to explore the efficacy of different therapeutic interventions.</description>
    </item> <item>
      <title>Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. (Article)</title>
      <link>http://repub.eur.nl/res/pub/2544/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>Transcription factor Sp1 has been implicated in the expression of many genes. Moreover, it has been suggested that Sp1 is linked to the maintenance of methylation-free CpG islands, the cell cycle, and the formation of active chromatin structures. We have inactivated the mouse Sp1 gene. Sp1-/- embryos are retarded in development, show a broad range of abnormalities, and die around day 11 of gestation. In Sp1-/- embryos, the expression of many putative target genes, including cell cycle-regulated genes, is not affected, CpG islands remain methylation free, and active chromatin is formed at the globin loci. However, the expression of the methyl-CpG-binding protein MeCP2 is greatly reduced in Sp1-/- embryos. MeCP2 is thought to be required for the maintenance of differentiated cells. We suggest that Sp1 is an important regulator of this process.</description>
    </item> <item>
      <title>The POU factor Oct-6 is required for the progression of Schwann cell differentiation in peripheral nerves. (Article)</title>
      <link>http://repub.eur.nl/res/pub/2529/</link>
      <pubDate>1996-01-01T00:00:00Z</pubDate>
      <description>The POU transcription factor Oct-6, also known as SCIP or Tst-1, has been implicated as a major transcriptional regulator in Schwann cell differentiation. Microscopic and immunochemical analysis of sciatic nerves of Oct-6(-/-) mice at different stages of postnatal development reveals a delay in Schwann cell differentiation, with a transient arrest at the promyelination stage. Thus, Oct-6 appears to be required for the transition of promyelin cells to myelinating cells. Once these cells progress past this point, Oct-6 is no longer required, and myelination occurs normally.</description>
    </item>
  </channel>
</rss>